BioVersys AG (XSWX:BIOV) Total Equity: CHF59.81 Mil (As of Dec. 2025)


XSWX:BIOV BioVersys AG XSWX:BIOV
4 GF Score
Price CHF26.00
View Full Analysis

What is BioVersys AG Total Equity?

BioVersys AG XSWX:BIOV 4 Total Equity is CHF59.81 Mil as of Dec. 2025. GuruFocus rates XSWX:BIOV with a GF Score™ of 4/100.

BioVersys AG's total equity for the quarter that ended in Dec. 2025 was CHF59.81 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

BioVersys AG Total Equity Historical Data

* Premium members only.

The historical data trend for BioVersys AG's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioVersys AG Total Equity Chart

BioVersys AG Annual Data
Trend Dec24 Dec25
Total Equity
10.68 59.81

BioVersys AG Semi-Annual Data
Jun24 Dec24 Jun25 Dec25
Total Equity 0.00 10.68 69.88 59.81
XSWX:BIOV
4GF Score
BioVersys AG XSWX:BIOV
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioVersys AG Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

BioVersys AG's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=90.636-30.825
=59.81

BioVersys AG's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=90.636-30.825
=59.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of CHF59.81 Mil mean?
BioVersys AG (XSWX:BIOV) has a Total Equity of CHF59.81 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for BioVersys AG and its competitors.
Is BioVersys AG's Total Equity too high?
BioVersys AG's current Total Equity is CHF59.81 Mil. Overall, BioVersys AG has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does BioVersys AG's Total Equity compare to VRTX and REGN?
BioVersys AG's Total Equity of CHF59.81 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for BioVersys AG and its competitors. BioVersys AG's current Total Equity is CHF59.81 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVersys AG stock overvalued right now?
BioVersys AG (XSWX:BIOV) has a current Total Equity of CHF59.81 Mil. The current Total Equity is CHF59.81 Mil. BioVersys AG's overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For BioVersys AG (XSWX:BIOV), the current Total Equity is CHF59.81 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioVersys AG Business Description

Other Exchanges BIOVz:UKW33:Germany
Address c/o Technologiepark, Hochbergerstrasse 60c, Basel, CHE, CH-4057
BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The Group focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others. It has one operating segment focusing on the research and development and prospective commercialization of antibiotics. Geographically, the company operates in Switzerland and France.
4GF Score

Get the complete analysis for XSWX:BIOV

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF26.00
Price